Company Overview: PetLife Pharmaceuticals

Industry News

11 Dec

PetLife Announces Positive Developments in Special Letter to Shareholders

PetLife Pharmaceuticals, Inc. (PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders: Dear Shareholder: PetLife (PTLF) is continuing to make significant strides towards developing the next generation of cancer medications for pets. We are...

Read more

12 Nov

Miami Vets Lead Alternative Pet Cancer Treatment with Escozine for Pets(TM)

Beverly Hills, CA / ACCESSWIRE / November 10, 2014 / PetLife Pharmaceuticals, Inc. (PTLF) today reported it is seeing Miami-area veterinarians leading the growing trend toward studying and using more cutting-edge treatment of pets to include increasing use of the Company’s Escozine for Pets nutraceutical product to treat pets...

Read more

3 Nov

PetLife Reports Positive Veterinary Clinical Pet Data on Escozine for Pets; Cancer-Diagnosed Pets’ Quality, and Longevity, of Life Improved and Extended

PetLife Pharmaceuticals, Inc. (PTLF) today announced it has received positive, preliminary clinical research data from an ongoing study of ten dogs or cats — diagnosed with cancer – that are being treated with Escozine for Pets(TM). The Study is conducted by Raul Jimenez, DVM, of the prestigious Biscayne Veterinary...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address